Oil prices hold sharp losses with focus on secondary India tariffs
Harry Kovelman, the Chief Medical (TASE:BLWV) Officer at Myomo, Inc. (NYSE:MYO), a company that has seen its stock surge over 22% in the past week and 34% over six months according to InvestingPro data, recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On March 12, Kovelman sold 30,000 shares of Myomo common stock in the open market. The shares were sold at an average price of $5.50 to $5.53 per share, amounting to a total transaction value of approximately $165,018. The transaction comes at a time when InvestingPro analysis suggests the stock is trading above its Fair Value, despite the company’s strong financial health with a current ratio of 3.22 and more cash than debt on its balance sheet.
Additionally, Kovelman acquired 3,553 restricted stock units on March 11, which became fully vested on the grant date. This acquisition was part of Myomo’s 2018 Stock Option and Incentive Plan. To cover income taxes related to the vesting of these restricted stock units, Kovelman sold an additional 1,496 shares on March 13 at $5.22 per share, totaling $7,809.
Following these transactions, Kovelman holds 96,477 shares of Myomo common stock.
In other recent news, Myomo Inc . announced impressive fourth-quarter 2024 financial results, reporting a record total revenue of $12.1 million, marking a 154% increase from the previous year and surpassing the consensus estimate of $9.9 million. The company also achieved a net loss of $0.01 per share, which was more favorable than the anticipated $0.02 per share loss. H.C. Wainwright responded to these results by raising the company’s stock price target to $9.50 from $7.50, maintaining a Buy rating. Myomo’s gross margin improved to 71%, and the company reported its first positive Adjusted EBITDA of $200,000. The quarter also marked a milestone for Myomo with positive free cash flow of $2.5 million. Looking forward, Myomo projects 2025 revenue between $50 million and $53 million, indicating strong expected growth. The company plans to focus on expanding its Medicare and international markets, as well as increasing its advertising spend to support future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.